{"symbol": "MCRB", "companyName": "Seres Therapeutics Inc", "exchange": "NASDAQ", "industry": "Pharmaceutical Preparation Manufacturing ", "website": "www.serestherapeutics.com", "description": "Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.", "CEO": "Eric Shaff", "securityName": "Seres Therapeutics Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2834, "employees": null, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Pharmaceutical Preparation Manufacturing "], "address": "200 Sidney St", "address2": null, "state": "Massachusetts", "city": "Cambridge", "zip": "02139-4218", "country": "US", "phone": "16179459626"}